Amyl therapeutics is a preclinical-stage biotechnology company pioneering a breakthrough approach to treating rare and severe peripheral protein misfolding diseases. By developing novel therapies that recognize and target multiple misfolded proteins, we aim to make a transformative impact on the lives of patients affected by systemic amyloidosis.
Our approach is shaped by an experienced team with deep drug development experience, and productive collaborations with world-class advisors and partners.
Chairman & Founder
Florent Gros has has held various leadership positions in venture, intellectual property and business transactions at Nestlé, Pasteur Merieux Connaught and Novartis in Switzerland, Europe and North America.
Valérie Calenda started her career as research scientist in Hematology and Virology at the Institut National de la Recherche Médicale (INSERM). After collaborating on a French/US research program relating to HIV at Davis University, she joined Transgene S.A., an affiliated company of Institut Mérieux, focusing on gene Therapy and immunotherapy.
Kenneth A. Buckfire
Kenneth A. Buckfire is the President and co-Founder of Miller Buckfire & Co. During his 30 year career in restructuring he has advised clients in a broad range of industries. In addition to co-founding Miller Buckfire in 2002 (acquired by Stifel Financial in 2012), he co-founded Marblegate Asset Management in 2008 which was sold when Stifel Financial acquired Miller Buckfire in 2012.
Pierre Vandepapelière, MD, PhD
Chief Executive Officer, Chief Medical Officer and Founder
Pierre has a large experience in development of vaccines, immunotherapeutics and biologicals. He held various positions and has led complex developments at GSK vaccines and in several Biotech companies.
Karine Goraj, PhD
Chief Scientific Officer
Karine is appointed as CSO of Amyl Therapeutics at the initiation of the Company (April 2021).